



Notification Number: 2018/163/F

## Pro Pharmacopoeia Technical Note No 1272, submitted for public inquiry

Date received : 12/04/2018

End of Standstill : 13/07/2018

### Message

Message 002

Communication from the Commission - TRIS/(2018) 00925

Directive (EU) 2015/1535

Translation of the message 001

Notification: 2018/0163/F

No abre el plazo - Nezahajuje odklady - Fristerne indledes ikke - Kein Fristbeginn - Viivituste perioodi ei avata - Καμμία έναρξη προθεσμίας - Does not open the delays - N'ouvre pas de délais - Non fa decorrere la mora - Neietekmē atlikšanu - Atidėjimai nepradedami - Nem nyitja meg a késések - Ma' jiftaħ il-perijodi ta' dawmien - Geen termijnbegin - Nie otwiera opóźnień - Não inicia o prazo - Neotvorí oneskorenia - Ne uvaja zamud - Määräaika ei ala tästä - Inleder ingen frist - He ce предвижда период на прекъсване - Nu deschide perioadele de stagnare - Nu deschide perioadele de stagnare.

(MSG: 201800925.EN)

#### 1. Structured Information Line

MSG 002 IND 2018 0163 F EN 12-04-2018 F NOTIF

#### 2. Member State

F

#### 3. Department Responsible

Direction générale des entreprises – SQUALPI – Bât. Sieyès -Teledoc 151 – 61, Bd Vincent Auriol - 75703

PARIS Cedex 13

d9834.france@finances.gouv.fr

tél : 01 44 97 24 55

#### 3. Originating Department

Agence nationale de sécurité du médicament et des produits de santé –

Direction des Politiques d'Autorisation et d'Innovation

Pôle pilotage et sécurisation des métiers, des processus et pharmacopée

143-147, boulevard Anatole France – F-93285 SAINT-DENIS CEDEX

contactspharmacopeefrançaise@ansm.sante.fr



tél. 01 55 87 41 57 – fax. 01 55 87 35 82

**4. Notification Number**

2018/0163/F - C30P

**5. Title**

Pro Pharmacopoeia Technical Note No 1272, submitted for public inquiry

**6. Products Concerned**

Monograph for pharmaceutical products

**7. Notification Under Another Act**

-

**8. Main Content**

The aim of the draft amendment to monograph No 1272 regarding sodium chloride capsules (50 mg – 1 g) is to:

- widen the therapeutic range,
- include the capsule size range, and
- amend the procedure for measuring the active ingredient (potentiometric method).

**9. Brief Statement of Grounds**

The texts, implemented in the 11th edition of the French Pharmacopoeia, will be published by way of a decision of the Director-General of the French National Agency for the Safety of Medicines and Health Products with the following wording: 'Having regard to Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, and in particular Notification No ...'

**10. Reference Documents - Basic Texts**

No basic text(s) available

**11. Invocation of the Emergency Procedure**

No

**12. Grounds for the Emergency**

-

**13. Confidentiality**

No

**14. Fiscal measures**

No



## 15. Impact assessment

-

## 16. TBT and SPS aspects

TBT aspect

No - the draft is neither a technical regulation nor a conformity assessment procedure.

SPS aspect

No - the draft is neither a sanitary nor phytosanitary measure.

\*\*\*\*\*

European Commission

Contact point Directive (EU) 2015/1535

Fax: +32 229 98043

email: [grow-dir2015-1535-central@ec.europa.eu](mailto:grow-dir2015-1535-central@ec.europa.eu)